Monitoring safety of single-low dose primaquine co-administered with ALu in routine healthcare practice: addressing potential implementation challenges and policy options for effective roll out

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202007653561223

Enrollment

600

Registered

2020-07-17

Start date

2020-03-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

Low dose primaquine plus ACT

NA because there is no control arm in this study

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria include: (i). All patients with uncomplicated P.falciparum malaria (ii). Participants with 1 year and above

Exclusion criteria

Exclusion criteria: Exclusion criteria include: (i). Pregnant women (ii). Lactating mother with children of 6 months and below

Design outcomes

Primary

Measure	Time frame
The proportion of health care who complied to the Primaquine Roll Out Monitoring Pharmacovigilance Tool PROMPT	—

Secondary

Measure	Time frame
The proportion of patients who came back at day 7 schedule for follow up	—

Countries

United Republic of Tanzania

Contacts

Public ContactPriscilla Mlay

Administrator

pmlay@ihi.or.tz+255620704425

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026